Twin Peaks Wealth Advisors’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8	Closed	-$14	–	1961
2026 Q1	$14	Buy	+8	New	+$23	﹤0.01%	2357

Other funds holding SXTP

KCM

Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Twin Peaks Wealth Advisors's SXTP Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of 60 Degrees Pharmaceuticals (SXTP) in Q2 2026, closing a stake of 8 shares — an estimated $14 sold.

Twin Peaks Wealth Advisors first reported a position in SXTP in Q1 2026 and held it in 1 quarter. The position peaked at $14 in Q1 2026. 8 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining 60 Degrees Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 8 60 Degrees Pharmaceuticals shares in Q2 2026, an estimated $14.
Twin Peaks Wealth Advisors first reported a position in 60 Degrees Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's 60 Degrees Pharmaceuticals position peaked at $14 in Q1 2026.
8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.